4-ethoxy-3-pyridinesulfonamide | 1229666-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-ethoxy-3-pyridinesulfonamide
• 英文别名: 4-ethoxypyridine-3-sulfonamide
• CAS: 1229666-21-0
• 化学式: C₇H₁₀N₂O₃S
• mdl: MFCD28505769
• 分子量: 202.234
• InChiKey: MQJPVIGZIDYFMM-UHFFFAOYSA-N

物化性质

• 熔点：
  179-180 °C
• 沸点：
  404.5±55.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  90.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-ethoxy-3-pyridinesulfonamide 、 3-硝基苯磺酰氯 以 乙腈 为溶剂， 以82%的产率得到3,8‐diethoxy‐1,10‐bis-(3‐nitrobenzenesulfonylimino)deca‐2,4,6,8‐tetraene‐2,9‐disulfonamide
  参考文献：
  名称：

  关于4-取代的3-吡啶磺酰胺与一些苯磺酰氯衍生物的反应产物

  摘要：

  研究了4-取代的3-吡啶磺酰胺1a，1b，1c，1d，1e与苯磺酰氯2a，2b，2c，2d，2e，2f在乙腈中的反应。取决于芳基磺酰氯和以良好的收率得到了以下四种类型的产品的反应条件的结构：3-氨磺酰基- 4- [R -1- arylpyridinium氯化物3，4，5，6，7，8; 1,10-双（3- nitrobenzenesulfonylimino）癸-2,4,6,8-四烯-2,9- disulfonamides 9，10，11，12 ; 1-取代的1,4-二氢-4-氧代-3- pyridinesulfonamides 13，14 ; 和4-甲氧基-3- [ N-（2,5-二氯苯基）磺酰基]磺酰胺化物15和16。讨论了这些反应的机理。

  DOI：

  10.1002/jhet.1013
• 作为产物：
  描述：

  4-ethoxy-3-pyridinesulfonamide hydrochloride 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 4.0h， 以94%的产率得到4-ethoxy-3-pyridinesulfonamide
  参考文献：
  名称：

  Carbonic anhydrase inhibitors: Synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides

  摘要：

  A series of novel 4-substituted-3-pyridinesulfonamides (2-27 and 31-33) have been synthesized and investigated as inhibitors of five isoforms of zinc enzyme carbonic anhydrase (CA, EC 42 11), that is, the cytosolic, ubiquitous isozymes CA I and II, and transmembrane isozymes CA IX, XII (cancer-associated) and XIV. Against the human isozymes hCA I, the new compounds showed inhibition constants in the range of 0.078-11.7 mu M, against hCA II in the range of 9.9-140 nM, against hCA IX in the range of 4.6-313 nM, against hCA XII in the range of 3.4-21.6 nM, and against hCA XIV in the range of 50.9-160 nM, respectively. Compounds 4, 6, 7, 9, 11-14, 19, 20, 22-24, 26, 27, 31 and 32 showed excellent hCA IX inhibitory efficacy, with inhibition constants of 4.6-12 0 nM, being much more effective as compared to the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND 4-[N'-(6-Chloro-7-cyano-1,1-dioxo-1,4,2-benzodithiazin-3-yl)hydrazino]-3-pyridinesulfonamide (31) is the prominent of the compounds due to its remarkable inhibitory activity toward hCA I (K(I)s = 0.078 mu M), hCA IX (K(I)s = 7.2 nM) and hCA XII (K(I)s = 3.4 nM).

  DOI：

  10.1016/j.ejmech.2010.02.020

文献信息

• [EN] ACYL SULFONAMIDES FOR TREATING CANCER<br/>[FR] ACYLSULFONAMIDES POUR LE TRAITEMENT DU CANCER
  申请人：BAYER AG

  公开号：WO2020216701A1

  公开（公告）日：2020-10-29

  The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6, Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.

  本发明提供了一般式(I)的酰基磺酰胺化合物：其中X、R1、R2、R3、R4、R5、R6、Ra和Rb如本文所述和定义的那样，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖性疾病的药物组合物，作为唯一药剂或与其他活性成分结合使用，以及治疗和/或预防疾病的方法，特别是癌症，更特别是KAT6A和/或KAT6B在局部扩增的癌症，所述方法包括向需要的受试者施用至少一种式(I)化合物的有效量。
• Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
  申请人：Inflazome Limited

  公开号：US11370776B2

  公开（公告）日：2022-06-28

  The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及式（I）化合物： 其中 Q 是 O 或 S，R1 是在 6 元环结构中含有至少一个氮原子的 6 元杂芳基，其中 R1 可任选被取代，R2 是在α 位被取代的环状基团，其中 R2 可任选被进一步取代。本发明进一步涉及此类化合物的盐、溶液剂和原药，涉及包含此类化合物的药物组合物，涉及此类化合物在治疗和预防医学紊乱和疾病中的用途，特别是通过抑制 NLRP3。
• SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS
  申请人：Inflazome Limited

  公开号：EP3649112A1

  公开（公告）日：2020-05-13
• ACYL SULFONAMIDES FOR TREATING CANCER
  申请人：Bayer Aktiengesellschaft

  公开号：US20220226279A1

  公开（公告）日：2022-07-21

  The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6′ R a and R b are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
• [EN] SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS<br/>[FR] SULFONYLURÉES ET SULFONYLTHIOURÉES EN TANT QU'INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2019008029A1

  公开（公告）日：2019-01-10

  The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.